WHI E+P Cost, Cost-Effectiveness, and Health-Economic Implications

At a glance

Parameter	Detail
Trial	Women's Health Initiative Estrogen + Progestin (WHI E+P)
N	16,608 postmenopausal women with intact uterus
Intervention	CEE 0.625 mg + MPA 2.5 mg daily (Prempro)
Comparator	Placebo
Planned duration	8.5 years (stopped early at 5.2 years median)
Primary endpoints	CHD (primary benefit), invasive breast cancer (primary safety)
Key result	HR 1.26 for breast cancer, HR 1.29 for CHD; global index exceeded stopping boundary (Rossouw et al., JAMA 2002)

Why the Economics of WHI E+P Matter

When the WHI E+P arm was halted in July 2002, the clinical findings were immediately converted into policy questions. If combined HRT raised breast cancer and coronary risk, was any level of spending on it justified? The original WHI E+P publication reported hazard ratios but did not include formal cost-effectiveness analysis. That work came later, from WHI investigators and independent groups, and it reshaped formulary decisions, insurance prior-authorization criteria, and individual prescribing conversations for more than two decades.

The economic story is more nuanced than the headline "HRT is dangerous" implied. Cost-effectiveness depends heavily on three variables: the patient's age at initiation, the indication (symptom relief vs. chronic disease prevention), and the time horizon of the model.

The Primary Cost-Effectiveness Models

Manson and Tosteson: The WHI-Linked Analysis

The most frequently cited economic evaluation came from investigators within the WHI network. Tosteson et al. (2008) used WHI E+P clinical event rates directly, combined with Medicare claims data for cost inputs and published utility weights for health states.

Their Markov model produced the following incremental cost-effectiveness ratios (ICERs) for CEE+MPA vs. no therapy, stratified by age:

"Dominated" means the intervention costs more and delivers worse outcomes than the comparator. For women aged 70 to 79 in the WHI E+P trial, the excess cardiovascular and thromboembolic events were frequent enough that no discount rate or time horizon made combined HRT economically defensible.

The UK Perspective: NICE and NHS Models

British health-technology assessment bodies ran parallel evaluations using WHI E+P data mapped to UK cost structures. The NICE menopause guideline (NG23, updated 2015) concluded that short-course HRT for vasomotor symptoms remained cost-effective at a £20,000-per-QALY threshold, but only when symptom severity was moderate to severe and duration stayed under five years. This aligned with the age-stratified findings from the US models: the value proposition depends almost entirely on symptom burden.

Drug Pricing: List Price vs. Net Price

Prempro (CEE 0.625 mg / MPA 2.5 mg) carried a wholesale acquisition cost (WAC) near $180 to $220 per month at brand peak. After WHI publication, generic conjugated estrogen/medroxyprogesterone combinations entered the market, dropping monthly costs to $15 to $40 depending on pharmacy and plan.

This pricing collapse changed the math. Models using brand pricing from the early 2000s showed ICERs roughly 3 to 5 times higher than models using post-generic pricing. A 2013 re-analysis using generic pricing found that for women aged 50 to 54 with moderate-to-severe hot flashes, the cost per QALY dropped below $10,000, well within any standard willingness-to-pay threshold (Lekander et al., Menopause 2013).

The practical takeaway: the generic availability of CEE+MPA components largely neutralized the cost argument against short-term symptomatic use. The economic objection to HRT was always strongest for the chronic-prevention indication, which the WHI E+P data dismantled on clinical grounds regardless of price.

Payer-Coverage Shifts After WHI

Commercial Insurers

Before July 2002, most commercial plans covered Prempro with tier-2 copays and no prior authorization. Within 18 months of the WHI E+P publication, surveys showed that roughly 40% of large employer plans had added step-therapy requirements or quantity limits for combined estrogen-progestin products. By 2006, several pharmacy benefit managers moved branded Prempro to tier 3 or non-preferred status, effectively steering patients toward generic alternatives or transdermal estradiol plus oral micronized progesterone.

Medicare Part D

When Part D launched in 2006, most plan formularies listed generic CEE+MPA on tier 1 or 2. Brand Prempro was tier 3 in the majority of plans surveyed by the Kaiser Family Foundation. The coverage structure reflected the post-WHI consensus: HRT was reimbursable for documented vasomotor symptoms, but not for osteoporosis prevention as monotherapy or cardiovascular risk reduction.

Prior Authorization Patterns

A 2010 analysis of pharmacy claims found that prior-authorization denial rates for HRT products rose from <5% pre-WHI to approximately 12% by 2008, with the highest denial rates in women over 60 initiating new prescriptions. This administrative friction, modest by oncology drug standards, still contributed to the prescribing decline that followed WHI.

The Individual Value Calculation

Population-level ICERs are useful for formulary committees. They are less useful for the 52-year-old patient sitting in clinic with night sweats disrupting her sleep four times per week. For that patient, the relevant question is: what does this therapy cost me, and what do I gain?

Out-of-Pocket Cost

With generic CEE+MPA priced at $15 to $40 per month (and with GoodRx-type discount programs sometimes pushing it under $10), the annual out-of-pocket burden for an insured patient is often $60 to $200. For uninsured patients using discount pharmacies, annual cost stays below $500.

Quality-of-Life Gains

Vasomotor symptom relief is difficult to monetize, but published utility studies assign a decrement of 0.05 to 0.15 QALYs per year for moderate-to-severe hot flashes. If combined HRT eliminates symptoms (as it did for roughly 75% of participants in the WHI E+P trial's symptom substudies), the utility gain over 3 to 5 years is measurable and meaningful.

Risk Offset

The WHI E+P hazard ratios translate to absolute risk increases that are small for younger women. The excess breast cancer risk was approximately 8 additional cases per 10,000 women-years in the overall cohort. For women aged 50 to 59, the absolute excess was lower. When weighted against symptom-driven quality-of-life gains and the low drug cost, the individual expected-value calculation often favors short-term use, a conclusion supported by the Endocrine Society's 2015 position statement and the 2022 North American Menopause Society position statement.

Limitations of WHI-Based Economic Models

Every cost-effectiveness analysis built on WHI E+P data inherits the trial's limitations:

1. Age distribution skew. Mean age at enrollment was 63. Only 33% of participants were 50 to 59. Economic models extrapolating to younger initiators rely on subgroup data with wider confidence intervals.

2. Single formulation tested. WHI used oral CEE+MPA exclusively. Transdermal estradiol plus micronized progesterone, now the preferred regimen in many guidelines, was not tested. Cost-effectiveness ratios for that combination remain modeled, not observed.

3. Adherence and crossover. Roughly 42% of the active-treatment group discontinued study medication. Intent-to-treat analysis dilutes both harms and benefits, which in turn compresses QALY differences and can make ICERs appear more favorable than per-protocol estimates.

4. Utility weights from different populations. Most models used EQ-5D or Health Utilities Index values derived from non-WHI populations. If WHI participants valued symptom relief differently from the reference samples, the QALY estimates shift.

5. Static pricing assumptions. Early models used brand pricing that became obsolete within five years. Even models using generic pricing rarely account for year-to-year pharmacy benefit redesigns.

What Happened to Prescribing Volume

The economic consequences of WHI extended beyond formal cost-effectiveness. Prempro prescriptions fell from approximately 22 million annually in 2001 to under 7 million by 2004. Total HRT prescriptions (all formulations) dropped by roughly 50% between 2002 and 2007. This prescribing collapse reduced aggregate drug spending on menopausal hormones by billions of dollars but also left a substantial population of symptomatic women untreated or undertreated. The 2017 WHI cumulative follow-up analysis noted that the benefits of HRT for younger women had been underappreciated in the initial reaction to the trial (Manson et al., JAMA 2017).

The irony is economic: the population-level cost savings from reduced HRT prescribing may have been partially offset by increased healthcare utilization for untreated vasomotor symptoms, insomnia, and genitourinary syndrome of menopause. No published model has fully quantified this offset.

Current Pricing and Access (2026)

Generic CEE 0.625 mg + MPA 2.5 mg tablets remain available at $15 to $40 per month. Brand Prempro is still marketed but carries a WAC above $250 per month and is rarely dispensed. Most formularies cover generic combined HRT without prior authorization for women under 60 with documented vasomotor symptoms. Access barriers are minimal for this specific therapy, though they increase for newer formulations like tissue-selective estrogen complexes (Duavee) or combination estradiol/progesterone capsules (Bijuva), which carry higher copays and more frequent prior-authorization requirements.

Frequently asked questions

›Was combined HRT ever considered cost-effective for disease prevention?

Pre-WHI observational data suggested HRT was cardioprotective, which made prevention-oriented cost-effectiveness models look favorable. After the WHI E+P trial showed increased CHD and breast cancer risk, no credible model supported combined HRT for chronic disease prevention at any standard willingness-to-pay threshold.

›How much does generic Prempro cost per month in 2026?

Generic conjugated estrogen plus medroxyprogesterone acetate costs approximately $15 to $40 per month at most US pharmacies. Discount programs can reduce this further. Brand Prempro exceeds $250 per month but is rarely dispensed.

›What is the cost per QALY for combined HRT in younger symptomatic women?

For women aged 50 to 54 with moderate-to-severe vasomotor symptoms, economic models using generic pricing estimate the cost per QALY at under $10,000 to $27,000, well below the commonly used $50,000 to $100,000 willingness-to-pay threshold.

›Did insurance coverage for HRT change after the WHI results?

Yes. Many commercial plans added step-therapy requirements, moved brand Prempro to higher copay tiers, and increased prior-authorization rates. Generic combined HRT remained broadly covered, especially for symptomatic indications.

›Why did HRT prescriptions drop so dramatically after 2002?

The WHI E+P finding of increased breast cancer and CHD risk led to FDA label changes, media coverage, revised society guidelines, and payer restrictions. Combined, these factors reduced total HRT prescriptions by roughly 50% within five years.

›Are transdermal HRT formulations more cost-effective than oral CEE+MPA?

Transdermal estradiol plus micronized progesterone was not tested in WHI. Observational data and some models suggest a more favorable risk profile, but transdermal products generally cost more ($40 to $120 per month), so cost-effectiveness depends on whether the safety advantage translates to fewer adverse events and lower downstream costs.

›Does Medicare Part D cover combined HRT?

Most Medicare Part D plans cover generic CEE+MPA on tier 1 or 2 for documented vasomotor symptoms. Brand Prempro is typically tier 3 or non-preferred. Coverage for HRT solely for osteoporosis prevention is inconsistent.

›How did the WHI prescribing drop affect healthcare costs overall?

Aggregate spending on menopausal hormones fell by billions of dollars. However, no published model has fully quantified potential offsetting costs from increased healthcare utilization for untreated vasomotor symptoms, insomnia, and genitourinary syndrome of menopause.

›Should individual patients use cost-effectiveness data to decide on HRT?

Population-level ICERs inform formulary and policy decisions. For individual patients, the more relevant inputs are out-of-pocket cost (often under $200 per year for generic HRT), personal symptom severity, and absolute risk of adverse events based on age and health profile.

›What are the main limitations of WHI-based economic analyses?

Key limitations include the trial's older enrollment population (mean age 63), testing only one formulation (oral CEE+MPA), high discontinuation rates (42%), reliance on utility weights from non-WHI populations, and pricing assumptions that became outdated as generics entered the market.

References

• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. PubMed
• Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care. 2008;14(9):605-615. PubMed
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. PubMed
• The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. PubMed